Disease‐modifying Drugs for Multiple Sclerosis in Japan: A Focus on the 2017 Japanese Guidelines and the 2018 Supplement

Clinical and Experimental Neuroimmunology - United Kingdom
doi 10.1111/cen3.12502
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics

Archives of Neurology
1999English

Disease-Modifying Therapy in Multiple Sclerosis: Two Guidelines (Almost) Passing in the Night

Multiple Sclerosis
Neurology
2018English

How to Use the New 2017 Japanese Guidelines for Multiple Sclerosis and Neuromyelitis Optica

Clinical and Experimental Neuroimmunology
NeuroscienceNeurologyImmunologyMicrobiology
2017English

When and How Disease-Modifying Drugs for Multiple Sclerosis Should Be Changed in Daily Practice

Clinical and Experimental Neuroimmunology
NeuroscienceNeurologyImmunologyMicrobiology
2017English

Disease Modifying Treatments and Symptomatic Drugs for Cognitive Impairment in Multiple Sclerosis: Where Do We Stand?

Multiple Sclerosis and Demyelinating Disorders
AllergyImmunologyNeurology
2017English

Multiple Sclerosis Disease-Modifying Therapy and Pregnancy

Multiple Sclerosis
Neurology
2016English

Comparing the Cost-Effectiveness of Disease-Modifying Drugs for the First-Line Treatment of Relapsing-Remitting Multiple Sclerosis

Journal of Managed Care Pharmacy
2009English

The Association of Adherence to Disease-Modifying Drugs and Out-Of-Pocket Costs in Patients With Multiple Sclerosis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Infections in Patients With Multiple Sclerosis: Implications for Disease-Modifying Therapy

Acta Neurologica Scandinavica
MedicineNeurology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy